Select a medication above to begin.
Synagis
palivizumab
Adult Dosing .
Adult dosing is currently unavailable or not applicable for this drug.
Peds Dosing .
- Dosage forms: INJ: 50 mg per 0.5 mL, 100 mg per mL
RSV prophylaxis, high-risk pts
- [<1 yo at start of RSV season]
- Dose: 15 mg/kg/dose IM qmo; Start: before RSV season or ASAP if during season; Max: 5 doses/season, may consider >5 doses if RSV dz activity persists at high levels; Info: for use in pts born <29 wk gestation, pts w/ CLD of prematurity, significant congenital heart dz, airway abnormalities or neuromuscular dz w/ impaired airway clearance, severe immunocompromise, CF w/ CLD or nutritional compromise, or undergoing cardiac transplantation during RSV season; give additional dose ASAP postop if undergoing cardiopulmonary bypass; D/C if hospitalized for breakthrough RSV
- [1-2 yo at start of RSV season]
- Dose: 15 mg/kg/dose IM qmo; Start: before RSV season or ASAP if during season; Max: 5 doses/season, may consider >5 doses if RSV dz activity persists at high levels; Info: for use in pts w/ CLD of prematurity requiring medical support w/in 6mo of start of RSV season, severe immunocompromise, CF w/ manifestations of severe lung dz or weight for length <10th percentile, or undergoing cardiac transplantation during RSV season; give additional dose ASAP postop if undergoing cardiopulmonary bypass; D/C if hospitalized for breakthrough RSV
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
Drug Interactions .
Overview
palivizumab
antiviral monoclonal antibody
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- anaphylaxis
- hypersensitivity rxn
- thrombocytopenia, severe
Common Reactions
- fever
- rash
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Look/Sound-Alike Drug Names
Synagis confused with: Synvisc
Pregnancy/Lactation .
Pregnancy
Clinical Summary
N/A; drug unlikely to be used during pregnancy based on indication
Lactation
Clinical Summary
N/A; drug unlikely to be used while breastfeeding based on indication
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: other; Half-life: 20 days (patients <24 mo)
Subclass: Respiratory Syncytial Virus (RSV)
Mechanism of Action
binds to A antigenic site of RSV F protein (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.